Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol

TARRYTOWN, N.Y. , Aug. 14, 2019 /PRNewswire/ — Adding evinacumab reduced LDL cholesterol by 49% in patients with homozygous familial hypercholesterolemia, compared to lipid-lowering therapies alone Evinacumab was generally well-tolerated, and all evinacumab patients completed the six-month

Original Source